https://clinicaltrials.gov/ct2/show/NCT05394519 This one tests a mixture of semaglutide and cagrilintide. Cagrilintide is an analog of the hormone amylin, which helps regulate glucose levels by slowing the rate at which food leaves the stomach, reducing the secretion of glucose-releasing hormones, and increasing the secretion of insulin. Sound familiar??? There have been some animal studies that have shown cagrilinitide to improve glycemic control, reduce excess body weight, and lower cardiovascular risk.

This is fascinating. Interesting also is that Eli Lilly has such a major focus on diabetes and obesity medicine, as well as Alzheimer’s medicine. https://neurosciencenews.com/obesity-neurodegeneration-alzheimers-22412/?fbclid=IwAR1W2Ug0BDwxnWGVpgkKxF5tlMrjm7yz8wYs0ikEjZEoUIhVupSOsHp3xhU&mibextid=unz460

https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Tirzepatide%20Injection&st=c Mounjaro SHORTAGE: FDA declares 5mg and 10mg in shortage https://youtu.be/MMl304qe5Y0 Shortage expected to last through Feb.